Michael Cook, DO
Family Medicine · Jenkins, KYNPI 1144403288
Payments from drug & device makers
Across 273 payments — averaging $13.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$820
- GSK$530
- Kowa Pharmaceuticals America, Inc.$389
- Merck$363
- AstraZeneca$333
- Lilly USA, LLC$316
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,78099%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 54 | $820 |
| GSK | 39 | $530 |
| Kowa Pharmaceuticals America, Inc. | 32 | $389 |
| Merck | 34 | $363 |
| AstraZeneca | 18 | $333 |
| Lilly USA, LLC | 25 | $316 |
| Boehringer Ingelheim | 11 | $143 |
| Novo Nordisk | 8 | $129 |
| Grifols USA, LLC | 7 | $100 |
| Phathom Pharmaceuticals, Inc. | 9 | $80 |
| Bayer | 5 | $77 |
| Arbor Pharmaceuticals, Inc. | 6 | $73 |
| Indivior Inc. | 3 | $64 |
| Supernus Pharmaceuticals, Inc. | 4 | $59 |
| AbbVie | 3 | $47 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $45 |
| Novartis | 2 | $34 |
| Orexo US, Inc. | 2 | $30 |
| Amgen | 2 | $30 |
| Tonix Medicines, Inc. | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Ardelyx, Inc. | 1 | $22 |
| Vertex | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
How this compares
$3,800 in reported general payments places this provider in the 80th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 89 | $85,482 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 598 | $58,690 |
| RybelsusSemaglutide | 40 | $36,549 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $32,073 |
| HorizantGabapentin Enacarbil | 34 | $31,244 |
| LinzessLinaclotide | 53 | $28,200 |
| JardianceEmpagliflozin | 31 | $20,997 |
| Bydureon BciseExenatide Microspheres | 23 | $19,007 |
| MounjaroTirzepatide | 17 | $17,622 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $16,136 |
| EliquisApixaban | 19 | $14,320 |
| FarxigaDapagliflozin Propanediol | 12 | $12,633 |
| TradjentaLinagliptin | 16 | $11,743 |
| Pregabalin | 340 | $9,868 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $8,742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $129 | $122,031129 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $530 | $40,81567 claims |
| AbbVieLinzess, Restasis | $47 | $36,63066 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $333 | $32,77955 claims |
| Boehringer IngelheimJardiance, Tradjenta | $143 | $32,74047 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $73 | $31,24434 claims |
| Lilly USA, LLCMounjaro | $316 | $17,62217 claims |
| PfizerEliquis | $820 | $14,32019 claims |
| NovartisEntresto | $34 | $8,13612 claims |
| Indivior Inc.Suboxone | $64 | $6,72617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Jenkins
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.